Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-01-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes information about board approvals and cumulative guarantee amounts. It is a regulatory announcement about financing guarantees rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather updates on guarantee activities and related board opinions. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities and guarantees.
2025-01-24 Chinese
2025-02.关于盐酸安非他酮缓释片（XL）获得美国FDA新增生产场地批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving FDA approval for an additional production site for a specific drug. It includes details about the drug, regulatory approval, and potential impact on the company. The document is short (953 characters) and serves as a regulatory announcement rather than a detailed financial report or presentation. It does not contain financial statements, earnings data, or management discussion. It is not a report publication announcement since it does not mention an attached report or provide a link. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about FDA approval and operational update.
2025-01-13 Chinese
关于获得药品临床试验批准通知书的公告
Regulatory Filings Classification · 100% confidence The document is an official announcement from 普洛药业股份有限公司 regarding the approval of a clinical trial application for a drug by the National Medical Products Administration (国家药品监督管理局). It details the drug name, registration classification, approval numbers, and the clinical trial's scope. The document also discusses the drug's development, market data, and potential impact on the company. It is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is short (1411 characters), and it is clearly an announcement of a regulatory approval event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-01-02 Chinese
关于公司及下属公司获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding government subsidies received by the company and its subsidiaries during the year 2024. It details the amounts, types, and accounting treatment of these subsidies, including their impact on profits and assets. The document is a formal disclosure but does not contain comprehensive financial statements or detailed financial performance analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification or officer attestation, nor is it a brief summary or presentation. The document is a regulatory announcement about government grants and their accounting impact, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like earnings release or capital update. The document length (7152 characters) and content support this classification rather than a report publication announcement or a full report.
2025-01-01 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company for its subsidiaries. It includes specific contract details, guarantee amounts, terms, and financial data of the subsidiaries. The content focuses on the company's provision of guarantees for loans and bank acceptance bills for its subsidiaries, with no indication of it being a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details rather than just a notice of report availability. The document is not about board changes, voting results, or legal proceedings. It is a regulatory announcement about financing guarantees, which fits best under the category of Capital/Financing Update (CAP). The document length (7172 characters) and detailed financial and contractual information support this classification with high confidence.
2025-01-01 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about receiving a drug registration certificate from the national drug regulatory authority. It details the product name, approval, and impact on the company. There is no financial data, no mention of financial results, no meeting or voting information, no management changes, no legal proceedings, no capital or financing updates, and no regulatory certifications. The document is short (995 characters) and is an announcement of a regulatory approval event. It does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory announcement about a product approval, so it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-12-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.